Put Options

27 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$66.59 - $83.99 $3.74 Million - $4.71 Million
-56,100 Reduced 16.07%
292,900 $24.6 Million
Q2 2024

Aug 14, 2024

BUY
$63.15 - $72.88 $15.7 Million - $18.1 Million
248,600 Added 247.61%
349,000 $23.9 Million
Q1 2024

May 15, 2024

SELL
$71.58 - $87.29 $19.7 Million - $24 Million
-274,600 Reduced 73.23%
100,400 $7.35 Million
Q2 2023

Aug 14, 2023

SELL
$76.01 - $86.7 $15.2 Million - $17.3 Million
-200,000 Reduced 34.78%
375,000 $28.9 Million
Q1 2023

May 15, 2023

BUY
$77.31 - $88.08 $16.1 Million - $18.4 Million
208,400 Added 56.85%
575,000 $47.7 Million
Q4 2022

Feb 14, 2023

BUY
$62.32 - $89.47 $17.4 Million - $25.1 Million
280,000 Added 323.33%
366,600 $31.5 Million
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $25.6 Million - $29.2 Million
-430,000 Reduced 83.24%
86,600 $5.34 Million
Q2 2022

Aug 15, 2022

SELL
$57.72 - $65.01 $11.9 Million - $13.4 Million
-205,800 Reduced 28.49%
516,600 $31.9 Million
Q1 2022

May 16, 2022

BUY
$57.92 - $72.58 $5.21 Million - $6.52 Million
89,900 Added 14.21%
722,400 $42.9 Million
Q4 2021

Feb 14, 2022

BUY
$64.88 - $73.64 $11 Million - $12.5 Million
170,000 Added 36.76%
632,500 $45.9 Million
Q3 2021

Nov 15, 2021

SELL
$67.69 - $73.03 $2.73 Million - $2.94 Million
-40,300 Reduced 8.02%
462,500 $32.3 Million
Q2 2021

Aug 16, 2021

SELL
$63.47 - $69.35 $17.8 Million - $19.4 Million
-279,700 Reduced 35.74%
502,800 $34.6 Million
Q1 2021

May 17, 2021

SELL
$60.0 - $68.46 $16.2 Million - $18.5 Million
-269,600 Reduced 25.62%
782,500 $50.6 Million
Q4 2020

Feb 16, 2021

BUY
$56.65 - $64.55 $12 Million - $13.7 Million
212,100 Added 25.25%
1,052,100 $61.3 Million
Q3 2020

Nov 16, 2020

BUY
$62.1 - $78.08 $29.8 Million - $37.5 Million
480,000 Added 133.33%
840,000 $53.1 Million
Q2 2020

Aug 14, 2020

SELL
$72.34 - $84.0 $21.2 Million - $24.7 Million
-293,600 Reduced 44.92%
360,000 $27.7 Million
Q1 2020

May 15, 2020

SELL
$62.63 - $80.22 $275,572 - $352,968
-4,400 Reduced 0.67%
653,600 $48.9 Million
Q4 2019

Feb 14, 2020

BUY
$61.62 - $67.78 $7.85 Million - $8.64 Million
127,400 Added 24.01%
658,000 $42.8 Million
Q3 2019

Nov 14, 2019

SELL
$62.51 - $69.0 $6.23 Million - $6.88 Million
-99,700 Reduced 15.82%
530,600 $33.6 Million
Q2 2019

Aug 14, 2019

SELL
$61.87 - $69.38 $13.7 Million - $15.4 Million
-221,300 Reduced 25.99%
630,300 $42.6 Million
Q1 2019

May 15, 2019

SELL
$62.53 - $70.05 $24.4 Million - $27.4 Million
-390,800 Reduced 31.46%
851,600 $55.4 Million
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $13.8 Million - $18.1 Million
228,500 Added 22.54%
1,242,400 $77.7 Million
Q3 2018

Nov 14, 2018

SELL
$71.28 - $78.92 $37.1 Million - $41 Million
-519,800 Reduced 33.89%
1,013,900 $78.3 Million
Q2 2018

Aug 14, 2018

BUY
$64.88 - $75.68 $447,671 - $522,192
6,900 Added 0.45%
1,533,700 $109 Million
Q1 2018

May 15, 2018

SELL
$72.84 - $88.8 $54.9 Million - $66.9 Million
-753,800 Reduced 33.05%
1,526,800 $115 Million
Q4 2017

Feb 14, 2018

BUY
$71.15 - $83.52 $29.6 Million - $34.8 Million
416,200 Added 22.32%
2,280,600 $163 Million
Q3 2017

Nov 14, 2017

BUY
$72.11 - $85.47 $134 Million - $159 Million
1,864,400
1,864,400 $151 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $115B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.